Signaled by briefing documents posted by the FDA earlier in the week, the efficacy of solithromycin (soli) to treat community-acquired bacterial pneumonia (CABP) was not in dispute even before the agency's Antimicrobial Drugs Advisory Committee (AMDAC) met Friday to discuss new drug applications submitted by sponsor Cempra Inc. for the agent's oral and injectable formulations.